Wockhardt says MHRA passes Chikalthana plant; Biocon buys potent API facility;

> India's Wockhardt reported to the Bombay Stock Exchange that the U.K.'s MHRA inspected and passed its plant in Chikalthana, a facility that the FDA has banned and to which it has issued a warning letter. Report

> India's Biocon last week reported that it had bought from Vishakhapatnam-based Acacia Lifesciences a manufacturing facility that makes intermediates of potent active pharma ingredients (APIs). Report

> Merck Millipore, the CMO operation of Merck KGaA, has formed a collaboration with celares GmbH that will provide pegylation services to customers developing protein-based therapeutics and biosimilars. Release

> Egyptian regulators, who estimate that 2% of the products in pharmacies are counterfeits or expired, will collect them from pharmacies and make manufacturers accept returns of expired product. Story

Suggested Articles

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.

On the heels of last week's deal for 120 million Pfizer-BioNTech shots, Japan has locked down 120 million more vaccines from AstraZeneca.